Philikos BV
- Biotech or pharma, therapeutic R&D
Philikos is developing T-Guard, a novel immune-reset therapy currently in a Phase 1/2 clinical trial for diffuse systemic sclerosis. By selectively eliminating pathogenic immune cells while sparing healthy immunity, T-Guard has the potential to transform treatment of systemic sclerosis and other severe autoimmune diseases. Philikos is seeking investment and strategic partnerships to accelerate development and expand therapeutic applications.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}